Reference: Once-weekly semaglutide 72 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial by Sean Wharton, Paula Freitas, Jran Hjelmesth, Maria Kabisch, Kristian Kandler, Ildiko Lingvay, Maria Quiroga, Julio Rosenstock and W Timothy Garvey, 14 September 2025, The Lancet Diabetes & Endocrinology
The insurer also said it is eliminating an undisclosed number of positions, consolidating its real estate footprint, and renegotiating vendor contracts
When the clinic does respond to public reviews, the responses tend to use generic, copy-and-paste templated language rather than addressing the specific issue raised
GLP-1 receptor signalling promotes -cell glucose metabolism via mTOR-dependent HIF-1 activation [2]
More specifically, MT-II has been reported to suppress appetite dose-dependently